Market access intelligence for life sciences.
We help pharmaceutical companies launch every drug in Brazil at the price it is worth, within CMED rules and with no tax surprises.
Where your drug’s market access is decided
What we deliver
From official data to the recommendation that goes to CMED.
You get finished work, with every number traceable to its source. We start as a specialist advisory; the same modules grow into a platform.
- Lower risk of CMED setting your price ex officio
- A price argument backed by precedent and evidence
- Launch decisions with tax already built into the price
Services
Nine fronts, from price to access.
Pricing & market access strategy
Pricing and access strategy from launch through the lifecycle, including the Price Information Document (DIP) ready for CMED.
Regulatory intelligence
CMED category classification, Anvisa queue and timeline reading, and CMED, Conitec and ANS precedents.
Drug taxation
NCM classification under TIPI, PIS/Cofins and ICMS regimes, and their effect on Factory and Consumer Prices.
International reference pricing
Reference-country baskets built from official sources, and launch-sequence analysis across markets.
Payer negotiations
Evidence and positioning to negotiate with SUS, private health plans and public buyers.
Early evidence assessment
An early read on the evidence a submission will rely on.
Healthcare system assessment
How the system funds, assesses and prioritises care: SUS, private health plans and public procurement.
Go-to-market & access pathways
Access and reimbursement pathways planned market by market.
Market access landscape
Each market's access environment, to decide where and when to enter.
Why Mindsharp
What no one else brings to the same table.
Data the market does not have, people who know drug price regulation from the inside, and technology in service of judgment.
Proprietary data lake
Marketing authorization, regulated price and the CMED queue cross-referenced product by product in our own data lake, updated with every Official Gazette issue.
Insider knowledge of CMED
Specialists in economic regulation and CMED pricing methodology, with Pedro Bernardo, former Director of Economic Regulation at Interfarma, as associate.
Traceable to the official source
Every price, exchange rate and tax rate traces back to its origin: CMED, Anvisa, Central Bank, TIPI and the Official Gazette.
AI trained on expert judgment
We teach AI our team's skills. Repetitive work is automated and expert time goes to the decision.
International basket from official sources
Reference-country prices collected from each country's official sources and converted at the Central Bank PTAX rate.
Pricing, regulatory and tax together
One team covers all three domains. The tax effect is built into the price from the start, not added later.
Every number has a source. Every recommendation has a rationale.
Contact
Let's talk.
Tell us the product, the timeline and the question. We reply with the regulatory path and what the dossier needs.
